ICH E6(R2)-Mandy Liu
FDA 21 CFR Part 11 Compliance-Charles Yan
Comment on “ICH E9(R1): Estimands and Sensitivity Analyses in Clinical Trials”-Toshimitsu Hamasaki
To discuss problems with clinical development team - Kentaro Sakamaki
